Neonatal Seizure Emergency: First-Line to Third-Line Anticonvulsant Protocol for NICU

Neonatal Seizures: Emergency Recognition and Drug Management

Neonatal seizures are the most common neurological emergency in the NICU, occurring in approximately 1-3.5 per 1000 live births in term neonates and significantly higher rates in preterm infants. They are a critical marker of underlying brain injury and represent a medical emergency requiring rapid diagnosis of the underlying etiology and prompt anticonvulsant therapy. The NNF India, AAP, and WHO all recognize that timely, protocolized seizure management is essential to minimize ongoing excitotoxic brain damage.

Clinical Recognition of Neonatal Seizures

Neonatal seizures differ significantly from seizures in older children and adults. They are often subtle and may be missed without careful observation or EEG monitoring. The main clinical seizure types include:

• Subtle seizures: Most common in term neonates; include eye deviation, lip smacking, cycling movements, apnea, and autonomic changes (blood pressure or heart rate fluctuations)
• Clonic seizures: Rhythmic jerking of extremities (focal or multifocal); more reliably electrographic
• Tonic seizures: Sustained posturing of limbs or trunk; generalized tonic seizures in preterms often have no EEG correlate
• Myoclonic seizures: Rapid, single jerks; may indicate metabolic or structural etiology

Differentiation from Non-Seizure Movements

Jitteriness and benign neonatal sleep myoclonus must be distinguished from true seizures. Key differentiating features include: jitteriness is stimulus-sensitive and stops with gentle restraint, while seizures are not; jitteriness shows no eye deviation, whereas seizures often do; and sleep myoclonus occurs only during sleep and stops on waking.

Immediate Workup Before Drug Administration

While initiating anticonvulsant therapy, simultaneously evaluate for treatable causes. The mnemonic VITAMIN covers the key etiologies:

• V - Vascular (stroke, hemorrhage, HIE)
• I - Infection (meningitis, encephalitis, TORCH)
• T - Trauma (birth injury)
• A - Asphyxia and metabolic (hypoglycemia, hypocalcemia, hypomagnesemia, hyponatremia)
• M - Malformation (brain anomalies)
• I - Inborn errors of metabolism (pyridoxine-dependent epilepsy, nonketotic hyperglycinemia)
• N - Neonatal drug withdrawal

Urgent Blood Tests During Seizure

Test	Rationale	Target Value
Blood glucose	Hypoglycemia is the most common treatable cause	Above 45 mg/dL
Serum calcium	Hypocalcemia causes seizures	Above 7 mg/dL (ionized above 1.1 mmol/L)
Serum magnesium	Hypomagnesemia, often with hypocalcemia	Above 1.5 mg/dL
Serum sodium	Hyponatremia or hypernatremia	135-145 mEq/L
Blood gas	Assess for acidosis, which worsens seizure threshold	pH 7.25-7.45
Blood culture, LP	Rule out meningitis/sepsis	Sterile CSF, normal cell count

Clinical Pearl: Always correct hypoglycemia and hypocalcemia before or simultaneously with starting anticonvulsants. Seizures due to metabolic disturbances will not respond to anticonvulsants alone until the underlying metabolic abnormality is corrected.

First-Line: Phenobarbital Protocol

Phenobarbital is the undisputed first-line anticonvulsant for neonatal seizures globally, recommended by NNF India, AAP, WHO, and NICE guidelines. It controls seizures in approximately 50-60% of neonates when used as a single agent.

Phenobarbital Dosing Protocol

Phase	Dose	Route	Administration	Notes
Loading dose	20 mg/kg	IV	Over 15-20 minutes	Monitor HR, RR, and BP during infusion
Additional bolus 1	10 mg/kg	IV	Over 15 minutes	If seizure persists 15-20 min after loading
Additional bolus 2	10 mg/kg	IV	Over 15 minutes	Maximum total loading: 40 mg/kg
Maintenance	3-5 mg/kg/day	IV or PO	Once daily or divided BID	Start 12-24 hours after loading; check levels

Phenobarbital Monitoring

• Therapeutic serum level: 20-40 mcg/mL
• Side effects to monitor: Respiratory depression (most critical), hypotension, sedation, feeding difficulty
• Requires: Continuous pulse oximetry, cardiorespiratory monitoring, and respiratory support readiness (CPAP or ventilator)

Second-Line Options: Phenytoin/Fosphenytoin and Levetiracetam

When seizures persist after maximum phenobarbital loading (40 mg/kg), a second-line agent should be added. Two main options are available:

Phenytoin/Fosphenytoin

Parameter	Specification
Loading dose	15-20 mg/kg PE (phenytoin equivalents) IV
Rate	Over 20-30 minutes (maximum 1 mg/kg/min for phenytoin; 3 mg/kg/min for fosphenytoin)
Maintenance	4-8 mg/kg/day divided BID
Therapeutic level	10-20 mcg/mL (free phenytoin 1-2 mcg/mL)
Key risks	Cardiac arrhythmia, hypotension, extravasation necrosis (phenytoin only), erratic absorption

Levetiracetam (Increasingly Preferred Second-Line)

Parameter	Specification
Loading dose	40-60 mg/kg IV
Rate	Over 15 minutes
Maintenance	10-30 mg/kg/dose BID
Therapeutic level	Not routinely monitored (12-46 mcg/mL suggested)
Advantages	Minimal sedation, no cardiac toxicity, no drug interactions, renal excretion, available IV

The NEOLEV2 trial and other emerging evidence suggest that levetiracetam may be as effective as phenobarbital for first-line treatment with fewer adverse effects, though larger trials are ongoing. In Indian Level III NICUs where continuous EEG monitoring is available, levetiracetam is increasingly used as a second-line agent or even first-line in select cases per institutional protocols.

Third-Line: Midazolam for Refractory Seizures

Seizures refractory to both phenobarbital and a second-line agent require escalation to continuous infusion therapy. Midazolam is the most commonly used third-line agent in Indian NICUs.

Parameter	Specification
Loading dose	0.05-0.15 mg/kg IV over 5 minutes
Infusion rate	0.1-0.4 mg/kg/hr (titrate every 15-30 minutes)
Maximum rate	0.5 mg/kg/hr
Duration	24-48 hours after seizure control; then wean over 12-24 hours
Key risks	Respiratory depression (intubation usually required), hypotension, excessive sedation

Other Third-Line Agents

• Lidocaine infusion: 2 mg/kg IV loading over 10 minutes, then 4-6 mg/kg/hr infusion; requires continuous ECG monitoring; contraindicated if phenytoin has been used due to combined cardiac toxicity
• Pyridoxine trial: 100 mg IV given empirically during seizure with EEG monitoring if available; dramatic response indicates pyridoxine-dependent epilepsy; continue 30 mg/kg/day PO
• Topiramate: 5-10 mg/kg/day PO; limited neonatal data but used in some refractory cases

Stepwise Seizure Management Algorithm

1. Stabilize: Airway, breathing, circulation; ensure IV access
2. Correct metabolic causes: Glucose (D10W 2 mL/kg if below 45 mg/dL), calcium (calcium gluconate 10% 2 mL/kg if ionized calcium below 1.1 mmol/L)
3. Phenobarbital loading: 20 mg/kg IV; repeat 10 mg/kg twice if needed (max 40 mg/kg total)
4. If seizures persist: Levetiracetam 40-60 mg/kg IV or phenytoin 15-20 mg/kg PE IV
5. If still refractory: Midazolam bolus then infusion; ensure ventilatory support
6. Consider: Pyridoxine trial (100 mg IV), lidocaine infusion, or further investigation for inborn errors of metabolism
7. Continuous EEG monitoring: Initiate as soon as available to detect subclinical seizures and guide treatment

Indian NICU Considerations

In resource-limited Indian settings, EEG monitoring may not be continuously available. Amplitude-integrated EEG (aEEG) devices offer a practical alternative for many Level II and III NICUs. NNF India recommends that all NICUs treating neonatal seizures have access to at least aEEG for seizure detection and monitoring treatment response. HEAMAC neonatal care resources support Indian NICU teams by providing access to essential monitoring equipment and protocol references for standardized seizure management across facilities of varying capability levels.

Duration of Maintenance Therapy and Weaning

For acute symptomatic neonatal seizures (such as HIE-related seizures), current evidence supports early discontinuation of anticonvulsants:

• If seizures are controlled and neuroimaging does not show major structural abnormality, wean phenobarbital before discharge or within 2-4 weeks
• If the EEG or aEEG shows resolution of epileptiform activity, anticonvulsants may be stopped
• For neonates with structural brain lesions or persistent EEG abnormalities, longer maintenance therapy guided by pediatric neurology is indicated
• Avoid prolonged phenobarbital exposure in developing brains when possible; animal data suggests potential apoptotic neurodegeneration with prolonged use

Conclusion

Neonatal seizures demand a rapid, algorithmic approach that simultaneously addresses the underlying cause and provides effective anticonvulsant therapy. Phenobarbital remains the global first-line agent, with levetiracetam and phenytoin as established second-line options. Indian NICUs should maintain pre-calculated seizure drug dosing charts at every bedside, ensure access to aEEG monitoring, and train all nursing and medical staff in seizure recognition. With protocolized management, the majority of neonatal seizures can be controlled within the first three therapeutic escalation steps, minimizing ongoing neuronal injury and optimizing long-term outcomes.